君实生物(01877)涨超4%，截至发稿，涨3.99%，报26.06港元，成交额5942.86万港元。 公告称，期内公司营业收入增长主要来自商业化药品销售收入的增长，其中，核心产品特瑞普利单抗注 射液(商品名：拓益/LOQTORZI，产品代号：JS001)于国内市场实现销售收入约14.95亿元，同比增长约 40%。与此同时，公司持续落实"提质增效重回报"行动方案，加强费用管控与资源聚焦，亏损金额与上 年同期相比显著缩窄。截至报告期末，公司的货币资金及交易性金融资产余额合计32.70亿元，资金储 备较为充足。 消息面上，10月28日，君实生物发布公告，2025年前三季度，营业收入18.06亿元(人民币，下同)，同比 增长42.06%；归属于上市公司股东的净亏损5.96亿元，同比收窄35.7%；基本每股亏损0.60元。 ...

Core Viewpoint - Junshi Biosciences (01877) reported a significant increase in revenue and a reduction in net loss for the first half of 2025, indicating positive growth and operational improvements in its commercialized drug sales [1] Financial Performance - The company achieved a revenue of approximately 1.168 billion yuan, representing a year-on-year growth of 48.64% [1] - The net loss attributable to shareholders was about 413 million yuan, which narrowed by approximately 36% compared to the previous year [1] - Basic loss per share was reported at 0.42 yuan [1] Revenue Drivers - Revenue growth was primarily driven by the sales of commercialized drugs, with sales in the domestic market reaching 954 million yuan, a year-on-year increase of about 42% [1] - The reduction in losses was attributed to the increase in sales revenue of commercialized drugs compared to the same period last year [1] Strategic Initiatives - The company is implementing a "quality improvement and efficiency enhancement" action plan, focusing on more competitive and innovative R&D projects [1] - Efforts are being made to accelerate clinical development, reduce production costs, and enhance sales efficiency to further decrease losses [1] Market Expansion - Currently, the drug Tuoyi has been approved for 12 indications in China and has received approvals in 40 countries and regions, including Hong Kong, the US, the EU, India, the UK, Jordan, Australia, Singapore, the UAE, and Kuwait [1] - The global commercialization value of Tuoyi is gradually becoming evident, with expectations for accelerated sales as new indications are approved and enter the insurance system [1]